A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms D3FEAT
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2016 Status changed from not yet recruiting to recruiting.
- 17 Jul 2015 New trial record